All In Biotech

NDA 208379 · Medicure

Zypitamag

Pitavastatin Magnesium · Oral · HMG-CoA Reductase Inhibitor

Last checked: Nov 20, 2026Latest source record: Jan 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 14, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

112

25 Phase 3, 12 recruiting

FAERS reports

59

28 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 3, 2025.

ZYPITAMAG is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. Pediatric use information is approved for Kowa Co Ltd LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd marketing exclusivity rights, this drug product is not labeled with that information. ZYPITAMAG is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1 ).

Mechanism: Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very low density lipoproteins.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZYPITAMAG · PITAVASTATIN MAGNESIUM EQ 4MG BASE · TABLET, ORAL · Prescription
  • ZYPITAMAG · PITAVASTATIN MAGNESIUM EQ 1MG BASE · TABLET, ORAL · Discontinued
  • ZYPITAMAG · PITAVASTATIN MAGNESIUM EQ 2MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pitavastatin" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache6
  • death5
  • dyspnoea5
  • hospitalisation5
  • product dose omission issue5
  • pruritus5
  • pain4
  • arthralgia3
  • cardiac death3
  • constipation3
  • dizziness3
  • fall3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20182
20192
20205
20219
202222
20234
20244
20253
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zypitamag (Pitavastatin Magnesium)

2024 spending

$3.9M

Beneficiaries

2,520

8,859 claims

Per beneficiary

$1,559

$7.43 per unit

View as table
YearSpending
2020$240,641
2021$421,360
2022$2,602,511
2023$3,812,450
2024$3,928,731

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 274 on PubMed

Sponsor: Medicure

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.